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CASE STUDY
Two months ago, on routine physical examination
by family physician, a 58-year-old woman was diag-
nosed with a breast lump. She received appropriate
imaging, and a core biopsy confirmed invasive duc-
tal carcinoma that was hormone receptor–negative
and 3+ by immunohistochemistry for human epider-
mal growth factor-2 (HER2). Five weeks ago, the
woman underwent lumpectomy, and the final pathol-
ogy report recorded a 2.4-cm tumour, grade III with
lymphovascular invasion. One sentinel lymph node
was positive, and the remaining 11 nodes on the sub-
sequent axillary nodal dissection were negative, for
a total count of 1 of 12 lymph nodes involved. This
woman is otherwise healthy and is not taking any
medications. Her staging workup was negative. A
baseline multiple gated acquisition scan showed an
ejection fraction (EF) of 58%.
What trastuzumab-based regimen would you sug-
gest for this patient? A concurrent or sequential
approach?
DISCUSSION
Which Approach Is the Most Cardiac-safe?
More than 13,000 patients have been enrolled in tras-
tuzumab adjuvant trials so far, but the longest car-
diac follow-up to date is only 5 years. A look at the
adjuvant trastuzumab studies shows rates of grades
3 and 4 cardiac toxicity that range from 0.4% [with
the Breast Cancer International Research Group 006
docetaxel–carboplatin–trastuzumab (TCH) regimen] to
up to 4% (with a concurrent regimen containing an
anthracycline and a taxane, combined analysis) 1. The
HERA (Herceptin Adjuvant) trial reports a 0.6% rate
of symptomatic congestive heart failure with sequen-
tial trastuzumab; however, their patient population
was notably quite selective. The patients had to have
finished chemotherapy and then had to have an EF
above 55% to be eligible for randomization. Also,
patients experienced a median delay of about
8 months from surgery to first dose of trastuzumab
and also a significant delay from completion of the
anthracycline to the start of trastuzumab.
Because these individual trials were quite differ-
ent in their eligibility criteria, cardiac follow-up rec-
ommendations, and endpoint definitions, comparing
their cardiac toxicity results is quite difficult. The only
trial that is truly comparing concurrent and sequen-
tial approaches to trastuzumab is the North Central
Cancer Treatment Group (NCCTG) N9831 trial. The
updated 3-year cardiac follow-up of that trial now
shows a cardiac event rate of 2.8% in the sequential
trastuzumab arm as compared with 3.3% in the con-
current arm 2, a difference that is not as marked as
initially thought—likely less than 1%.
It does appear that a non-anthracycline trastuzu-
mab protocol—that is, TCH—is the most cardiac-safe.
Furthermore, there is no significant difference in car-
diac toxicity between the concurrent and sequential
approaches.
Which Approach Is the Most Effective?
The key trial that will answer the question of effec-
tiveness is NCCTG N9831, which randomized patients
to no trastuzumab, concurrent trastuzumab, or se-
quential trastuzumab with a chemotherapy backbone
of cyclophosphamide–doxorubicin (AC) followed by
weekly paclitaxel. The results of the unplanned in-
terim analysis presented at the 2005 American Soci-
ety of Clinical Oncology meeting demonstrated that
the concurrent approach was superior to the sequen-
tial approach, and furthermore, that the sequential
approach was no better than control. However, given
that the interim analysis was unplanned, most clini-
cians will not make treatment decisions based on its
results.
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Another trial presented at the 2007 San Anto-
nio Breast Cancer Symposium also indicated that
the sequential approach may not be as effective.
The randomized PACS-04 study was initially de-
signed to compare 6 cycles of fluorouracil–epi-
rubicin–cyclophosphamide (FEC100) to 6 cycles of
epirubicin given concurrently with docetaxel 3.
Then, in a second randomization, HER2-positive
patients were randomized to receive or not receive
trastuzumab after completion of chemotherapy. The
authors presented their results with a median fol-
low-up of 4 years. No significant improvement was
observed in disease-free survival [hazard ratio (HR):
0.86; p = 0.41] or overall survival (HR: 1.27; p = not
available). There did appear to be initial efficacy
in the first 18 months, but the effect was lost over
the next 2 years. Numerically, fewer metastatic
events were seen on the trastuzumab arm.
And so PACS-04 is the first negative adjuvant tras-
tuzumab trial. Why, given all the previous trials, was
an additional benefit of trastuzumab not seen in its
patients?
The PACS-04 patients all received adequate
anthracyclines, and about 50% had an adequate
dose of a taxane. The results seen are similar to
those from the unplanned analysis of the sequen-
tial arm of NCCTG N9831 [hazard ratio (HR): 0.87].
Also, it is concerning that, with sequential therapy,
a benefit initially seen is lost with longer follow-
up. The suggestion is that trastuzumab may have a
cytostatic effect when given sequentially as com-
pared with a cytotoxic effect when given concur-
rently.
Why was no benefit seen with the sequential
approach in the PACS-04 trial, when a benefit was
observed in HERA (Table I) 3,4? One explanation may
be that the patients in HERA did not receive adequate
chemotherapy, and that in the presence of third-
generation regimen, the benefit of trastuzumab is
seen only in a concurrent and not in a sequential
regimen.
The evidence from concurrent regimens has
previously showed a benefit in the range of about
50% reduction in the relative risk of disease recur-
rence and 40% reduction in the relative risk of
mortality. And notably, these results occurred de-
spite a backbone of third-generation chemotherapy
regimens such as AC followed by paclitaxel or by
docetaxel.
What Should the Recommendation Be for the
Current Patient?
Early data appear to indicate that a concurrent ap-
proach is more efficacious than a sequential approach.
Furthermore, the additional cardiac toxicity appears
not to be quite as marked as initially thought, and may
be even further mitigated with the use of a non-anthra-
cycline-based concurrent regimen. The key NCCTG
N9831 trial results are eagerly awaited, and their avail-
ability later in 2008 will probably settle this debate.
Coming back to the specific patient, I suggest that
she be offered a concurrent trastuzumab regimen with
appropriate cardiac follow-up.
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TABLE I Sequential approach with trastuzumab: HERA compared with
PACS-04
Trials
HERA PACS-04
Median follow-up (years) 2 4
Anthracyclines (%) 96 100
Anthracyclines and taxanes (%) 26 50
Node-positive (%) 32 100
Disease-free survival 0.64 0.86
(p<0.0001) (p=0.41)
Overall survival 0.66 1.27
(p=0.0115) (p=NA)
NA = not available.